Generic Name: decitabine/cedazuridine
Drug Class: Chemotherapy Medications
Company: Taiho
Approval Status: Approved
Generic Version Available: No
Drug Indication
Inqovi is a combination of two oral chemotherapy drugs, decitabine and cedazuridine, used for the treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia.
General Info
Inqovi combines decitabine, a nucleoside metabolic inhibitor, and cedazuridine, a DNA methylation inhibitor. The two drugs affect processes involved in cell proliferation and may restore normal cell growth. Studies showed that about half of people who needed blood transfusions for myelodysplastic syndromes no longer did so after using Inqovi. The combination pill produces drug levels similar to those of IV infusions. Inqovi was first approved in July 2020.
Dosage
Dosing Info:
Inqovi is a tablet taken once daily for five consecutive days in each monthly cycle.
Side Effects
Common adverse reactions include fatigue, mouth sores, muscle and joint pain, headache, nausea, diarrhea, constipation, decreased appetite, rash, dizziness, edema (swelling), cough, shortness of breath, pneumonia and elevated liver enzymes. Mylotarg can cause depletion of hemoglobin (anemia), white blood cells (neutropenia) and platelets (thrombocytopenia), which can lead to infections and bleeding. It can cause fetal harm if used during pregnancy.
For More Info: https://www.inqovi.com/
Patient Assistance Program Info: https://www.taihopatientsupport.com/
Last Reviewed: July 8, 2020
